Eli Lilly and Company

Jianghuai Xu

Donmienne Doen Mun Leung

Ying Tang

Jirong Lu

Adam Robert Mezo

Ling Liu

Peter Edward Vaillancourt

Francisco Alcides Valenzuela

Michael James Bacica

Donmienne Doen Leung

Purva Vivek Trivedi

Matthew D Linnik

James Thomas Parker

Yiqing Feng

The present invention relates to compounds that bind to human vascular endothelial growth factor A (VEGFA) and human angiopoietin-2 (Ang2), and may be useful for treating angiogenic eye diseases, such as diabetic and other proliferative retinopathies, and for cancer, especially solid tumors driven by VEGFA and Ang2, including gastric, lung, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.

VEGFA/Ang2 Compounds

The present invention relates to antibodies that bind human angiopoietin-2 (Ang2), and may be useful for treating cancer alone and in combination with VEGF pathway inhibitors, especially cancer driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, and breast cancers.

Ang2 antibodies

The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (VEGFR2) and human angiopoietin-2 (Ang2), and may be useful for treating cancer, especially solid tumors driven by VEGFR2 and Ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.

VEGFR2/Ang2 compounds

Growing community of inventors

San Diego, CA, United States of America

Jianghuai Xu